sfa 4:0

SFA 4:0 refers to a short‑chain saturated fatty acid comprised of four carbon atoms, commonly known as butyric acid or butanoic acid. Structurally, butyric acid is the simplest of the saturated fatty acids beyond C2:0 and C3:0 varieties, with the straight‑chain chemical formula CH3CH2CH2COOH. It is classified as a saturated fatty acid because it contains no double bonds between carbon atoms; however, unlike long‑chain saturated fatty acids such as palmitic (C16:0) and stearic (C18:0) acid, butyric acid is categorized among short‑chain fatty acids (SCFAs). The designation "4:0" represents its four‑carbon backbone and zero unsaturation. SCFAs are distinguished both chemically and functionally from medium and long‑chain saturated fatty acids because their short carbon length allows them to be rapidly absorbed and metabolized, often serving as key metabolic substrates. Butyric acid is unique among saturated fatty acids because it has both dietary and endogenous sources. In the Western diet, butyric acid is found in dairy products, particularly high‑fat cheeses, butter, cream, and whole milk, where it typically represents a small percentage of the total fat content. In addition to dietary sources, butyric acid is produced within the human gastrointestinal tract by bacterial fermentation of dietary fibers and resistant starches. Beneficial gut microbes such as Faecalibacterium prausnitzii, Roseburia spp., and certain Clostridium clusters degrade non‑digestible carbohydrates into SCFAs, including acetate, propionate, and butyrate, with butyric acid being a principal end product. Historically, butyric acid was first isolated and characterized in the early 19th century by French chemist Michel Eugène Chevreul, who identified the compound as responsible for the distinctive smell of rancid butter. Its name originates from "butyrum," the Latin word for butter. Today, butyric acid is recognized not just for its sensory properties but for its physiological importance. In the colon, butyric acid serves as a primary energy source for colonocytes—the epithelial cells lining the large intestine. Unlike many other fatty acids that are transported and metabolized systemically, butyric acid is largely utilized locally in the gut, where it promotes cellular health and supports the integrity of the gut barrier. From a chemical classification standpoint, butyric acid belongs to the larger family of fatty acids and is a member of the short‑chain subgroup. Fatty acids vary widely in chain length and degree of saturation, characteristics that determine their physical properties and metabolic effects. Butyric acid's relatively short chain gives it distinct solubility and metabolic profiles compared with longer saturated fatty acids commonly implicated in raising LDL cholesterol levels when consumed in excess. While long‑chain saturated fatty acids such as myristic and palmitic acids have been associated with adverse effects on plasma lipid profiles, butyric acid demonstrates unique metabolic roles, particularly in the gastrointestinal tract and systemic immune modulation. Although official Recommended Dietary Allowances (RDAs) and Tolerable Upper Intake Levels (ULs) have not been established for butyric acid by authoritative bodies like the NIH Office of Dietary Supplements or the National Academies' Dietary Reference Intakes—largely because human physiology can synthesize and derive significant amounts from microbiota activity—interest in its functions continues to expand. Unlike essential fatty acids (such as omega‑3 and omega‑6), which must be obtained from the diet, butyric acid is not considered essential in the strict sense. However, its short‑chain structure and biological effects have made it a focus of nutrition science and gastrointestinal health research.

Butyric acid is biologically active well beyond its modest representation in the diet. As a short‑chain fatty acid, it is primarily recognized for its crucial role in colonic health. Butyric acid serves as the principal energy substrate for colonocytes, the epithelial cells of the large intestine. Unlike long‑chain fatty acids that are absorbed in the small intestine and transported via chylomicrons, butyric acid is absorbed directly by colonocytes and oxidized locally, fueling cellular metabolism and supporting mucosal integrity. Healthy levels of butyric acid in the colon have been associated with maintenance of the gut barrier, which prevents translocation of pathogens and endotoxins into systemic circulation. One of the key mechanistic insights about butyric acid lies in its role as a signaling molecule. Butyric acid and its conjugate base, butyrate, act on G‑protein coupled receptors (such as GPR41 and GPR43) present on intestinal and immune cells, influencing immune responses and inflammatory pathways. It has been shown to inhibit histone deacetylases (HDACs), epigenetically modulating gene expression that regulates inflammation and cell proliferation. These properties have implications for chronic inflammatory conditions such as inflammatory bowel disease (IBD), where butyric acid may help attenuate inflammatory cascades. Beyond the colon, butyric acid plays roles in systemic metabolic regulation. Emerging research indicates that butyric acid may improve glycemic control and body weight regulation by activating AMP‑activated protein kinase (AMPK) pathways and enhancing insulin sensitivity in adipose tissue and skeletal muscle. For example, in studies of dietary patterns that increase butyric acid production through fermentable fibers, improvements in markers of insulin resistance and glucose tolerance have been observed. Although much of this evidence comes from preclinical animal models and small human studies, it suggests potential benefits for metabolic conditions. Butyric acid also influences immune function. SCFAs including butyrate modulate the function of regulatory T cells and the production of anti‑inflammatory cytokines, supporting a balanced immune response. This immunoregulatory effect may contribute to reduced risk of certain inflammatory disorders and support overall immune homeostasis. Gastrointestinal health is perhaps the most extensively studied domain of butyric acid benefits. Butyric acid promotes mucus production and tight junction assembly in the gut epithelium, strengthening the mucosal barrier. It also contributes to maintaining a balanced gut microbiome by lowering colonic pH and inhibiting pathogenic bacteria, thereby fostering a hospitable environment for beneficial microbes. In conditions like irritable bowel syndrome (IBS) and ulcerative colitis, clinical observations suggest that butyric acid—either through endogenous production or supplementation—can help reduce symptoms such as abdominal pain and diarrhea. Recent human cohort research has explored associations between dietary butyric acid intake and broader health outcomes. For instance, analyses from large nutrition surveys indicate that higher butyric acid intake is associated with lower all‑cause mortality among adults with chronic kidney disease, hinting at potential benefits in systemic inflammatory states and organ health beyond the gut. While mechanisms remain under investigation, these findings align with butyric acid's anti‑inflammatory signaling properties and metabolic effects. However, while the functional benefits of butyric acid are increasingly recognized, researchers caution that direct dietary intake represents only a portion of total butyric acid availability in the body. Endogenous production by the gut microbiota from dietary fibers may be more significant for colonic and systemic effects than direct intake from foods. Therefore, dietary patterns that include adequate fermentable fibers—not just high‑butyric acid foods—are critical to maximizing the physiological benefits of this nutrient.

Unlike essential vitamins and minerals, butyric acid (SFA 4:0) is not assigned an official Recommended Dietary Allowance (RDA) because the human body can produce significant quantities through microbial fermentation of dietary fibers. authoritative sources do not provide numeric intake recommendations for short‑chain fatty acids, and nutrient labeling standards do not list butyric acid Daily Values on nutrition fact panels. Instead, dietary guidance emphasizes overall fat intake distribution and quality. For instance, the U.S. Dietary Guidelines recommend limiting saturated fat intake to less than 10% of total calories, without specifying individual fatty acids such as butyric acid. Even though there is no quantified RDA, obtaining butyric acid through diet and supporting its internal production is considered beneficial for gut and metabolic health. Butyric acid production in the colon depends on consuming fermentable fibers—including resistant starches, inulin, pectins, and beta‑glucans—found in whole grains, legumes, fruits, and vegetables. Dietary patterns that include ample fiber facilitate the growth of beneficial microbiota capable of producing butyric acid and other SCFAs. Some experts suggest that a daily fiber intake of at least 25–30 grams or more can help optimize SCFA production, including butyrate, though this is an indirect guideline rather than a formal recommendation. Factors Affecting Needs Several factors influence butyric acid availability and apparent need. Individuals with dysbiosis, inflammatory bowel conditions, or low dietary fiber may have reduced microbial production of butyric acid, potentially increasing the importance of dietary intake and supplementation strategies designed to boost colonic butyrate levels. Similarly, aging, antibiotic use, and chronic diseases may alter gut microbiota composition and diminish SCFA production. Optimal Versus Minimum Because butyric acid production is intimately tied to dietary fiber fermentation, suggestions about "optimal" intake relate more to patterns that foster SCFA generation rather than specific gram amounts. Research suggests that diets rich in resistant starch, as found in cooled potatoes, legumes, and whole grains, can significantly raise butyrate concentrations in the colon, improving mucosal health. While absolute daily gram targets for butyric acid have not been defined, some observational data indicate potential benefits from intakes around 0.2–0.3 grams per day in certain populations. Clinical Contexts In therapeutic settings, oral butyrate supplementation—for example, via sodium or calcium butyrate preparations—has been explored in research for conditions such as ulcerative colitis and metabolic syndrome. Doses in clinical studies often range from a few hundred milligrams to several grams per day. However, these experimental dosing protocols should not be interpreted as general recommendations outside supervised medical contexts. In summary, although there is no official RDA, butyric acid needs are met through consuming a diet high in fermentable fibers and some dairy products that contain the fatty acid.

Because butyric acid is not classified as an essential nutrient with a defined RDA, there is no formal "deficiency" syndrome analogous to scurvy or rickets. However, low levels of butyric acid—particularly in the colon—have been associated with pathological conditions. Butyric acid depletion is often secondary to reduced microbial fermentation caused by low dietary fiber intake, dysbiosis, or damage to the colonic epithelium. This functional deficiency may manifest as compromised gut barrier integrity, chronic inflammation, and altered metabolic signaling. Common Clinical Manifestations Functional insufficiency of butyric acid production has been linked to gastrointestinal disturbances. Individuals with low butyrate concentrations in the colon may experience symptoms including increased bowel discomfort, bloating, changes in bowel habits (diarrhea or constipation), and greater susceptibility to inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. These conditions often exhibit reduced populations of butyrate‑producing bacteria, and correlational studies find lower luminal butyrate levels in affected patients compared with healthy controls. In addition to gastrointestinal symptoms, inadequate butyric acid availability may influence systemic metabolic processes. Some research suggests associations between low butyrate production and insulin resistance, increased adiposity, and metabolic syndrome features, although causality remains under investigation. At‑Risk Populations At‑risk groups for low butyrate production include individuals with chronically low fiber intakes, those with disrupted gut microbiota due to prolonged antibiotic use, and people with chronic gastrointestinal disease. Aging adults and individuals with metabolic disorders may also exhibit altered SCFA profiles. Chronic kidney disease patients, for instance, have been shown to benefit from dietary strategies that increase butyric acid intake, with higher intake associated with reduced all‑cause mortality in cohort studies. Diagnosis and Biomarkers There is no standardized blood test for "butyric acid deficiency." Laboratory assessment typically involves measuring fecal SCFA concentrations or using metabolomic profiling to infer colonic fermentation status. Clinicians may use symptom patterns, dietary history, and microbiome analyses to gauge functional butyrate status indirectly. Optimal colonic butyrate levels are not universally established but are often interpreted relative to population norms in research contexts.

Butyric acid (SFA 4:0) occurs naturally in a variety of foods, especially those high in dairy fats, and it is also produced endogenously in the colon by microbial fermentation of dietary fibers. Foods richest in butyric acid tend to be high‑fat dairy products such as hard cheeses, cream, butter, and whole milk. For example, grated low‑sodium Parmesan cheese provides among the highest concentrations of butyric acid per serving, often exceeding 1.5 grams per cup, making it a notable source for this short‑chain fatty acid. Similarly, light whipping cream and whole milk provide substantial amounts, highlighting dairy as a key dietary contributor of butyric acid. Cheeses of various kinds also contribute meaningful amounts. Hard goat cheese, Romano cheese, and cheddar varieties typically contain hundreds of milligrams of butyric acid per ounce. Butter—unsalted or salted—delivers high concentrations per tablespoon, and ghee (clarified butter) contains a similar profile, though concentrations may vary depending on processing. Even sweet foods containing butter, such as chocolate mousse or semisweet candies made with butter, can provide measurable levels of butyric acid, albeit alongside added sugars. It is important to note, however, that direct intake of butyric acid from foods generally comprises a minority of total SCFA exposure. The majority of butyric acid in the human colon is generated by the fermentation of dietary fiber and resistant starches by gut microbiota. Foods high in fermentable fibers—including legumes, whole grains, bananas (especially slightly underripe), oats, and cooked and cooled starchy foods like potatoes and rice—do not contain butyric acid per se but are substrates for microbial production of butyrate in the gut. Thus, a combination of dietary sources and fermentable fiber intake supports both direct and indirect availability of butyric acid. In general, individuals seeking to enhance butyric acid exposure should focus on balanced dietary patterns that combine high‑fat dairy (in moderation) with ample fiber‑rich plant foods. This facilitates endogenous production while contributing modest amounts of butyric acid through direct dietary intake.

Butyric acid displays a unique absorption and utilization profile compared with long‑chain fatty acids. After ingestion, a fraction of dietary butyric acid is absorbed in the small intestine; however, much of it reaches the colon where it is directly taken up by colonocytes. These epithelial cells preferentially oxidize butyric acid to produce ATP, making it a vital energy source that sustains the metabolic demands of the colonic mucosa. Because of this, butyric acid has high local bioavailability in the large intestine, where it exerts its primary physiological actions. Its absorption bypasses the need for incorporation into chylomicrons, as required for long‑chain fatty acids, allowing rapid uptake by colonic tissue. Enhancers of butyrate production do not always equate to increased direct dietary absorption but rather promote microbial conversion of fermentable substrates to butyrate in the colon. Resistant starches—such as those found in cooled rice and potatoes—along with soluble fibers like pectin and inulin, are particularly effective at stimulating microbial fermentation pathways that elevate local butyric acid concentrations. The composition of the gut microbiota plays a crucial role, as certain bacterial genera such as Faecalibacterium prausnitzii and Roseburia spp. are especially efficient at producing butyrate from these substrates. Factors that inhibit butyrate bioavailability include dysbiosis—disruptions in gut microbiota balance often caused by antibiotics or chronic inflammation—which reduces the population of butyrate‑producing bacteria. Conversely, prebiotic consumption and a diet high in fermentable fibers enhance butyrate production. Some food processing methods may also alter the matrix of fat and fiber, affecting the degree to which fatty acids are available for fermentation. Overall, butyric acid's bioavailability is tightly linked to both its direct ingestion and the intestinal environment facilitating microbial fermentation. Supporting gut health through dietary strategies that enhance the microbiome’s capacity to produce SCFAs maximizes the physiological impact of this short‑chain fatty acid.

Because butyric acid is not considered an essential nutrient with an official RDA, supplementation is not universally recommended for the general population. For most healthy individuals, achieving adequate butyric acid activity depends on dietary patterns that include fermentable fibers to stimulate endogenous production. Nonetheless, butyric acid supplements—often in the form of sodium butyrate, calcium butyrate, or encapsulated butyrate esters—are marketed to support gut health, particularly in individuals with gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome. Clinical interest in butyrate supplementation stems from its putative anti‑inflammatory and mucosal healing properties. Some clinical studies and practitioner reports suggest potential benefits for individuals with ulcerative colitis or those recovering from antibiotic‑related dysbiosis, where low butyrate production may contribute to persistent inflammation. Doses explored in research contexts vary but often range from a few hundred milligrams to several grams per day, tailored to therapeutic goals. Because direct evidence from large randomized controlled trials is limited, healthcare providers usually recommend a cautious approach, emphasizing dietary strategies to boost endogenous production before resorting to supplements. Supplements may benefit individuals with low fiber intake, gut barrier dysfunction, or specific clinical diagnoses associated with reduced SCFA production. They may also be considered for people with metabolic syndrome or obesity, given emerging evidence suggesting improvements in insulin sensitivity related to SCFA signaling pathways. However, because supplements are not regulated with the same rigor as pharmaceuticals, quality varies widely among products. Clinicians typically advise selecting supplements with clear labeling, third‑party testing, and evidence of stability and purity. Additionally, because butyrate has a pungent odor and taste, many supplements use enteric coatings to improve tolerability and targeted delivery to the colon. While adverse effects are uncommon, some individuals may experience gastrointestinal discomfort, including gas and bloating, when initiating butyrate supplementation. As with any supplement, consulting a healthcare provider is recommended—especially for individuals with chronic health conditions or those taking concurrent medications. Finally, emphasizing a diet rich in fermentable fibers and balanced macronutrients remains the foundational strategy for supporting butyric acid production and gut health.

Butyric acid has not been assigned a formal Tolerable Upper Intake Level (UL) by major nutrition authorities, largely due to the absence of evidence indicating toxicity at dietary levels. As an SCFA naturally produced in the colon and present in modest amounts in foods, typical exposure through diet does not approach thresholds associated with adverse effects. Experimental studies in animal models indicate that very high doses of butyrate can cause gastrointestinal irritation and metabolic disturbances, but these levels far exceed normal dietary intake. Case reports and supplement research suggest that gastrointestinal transient side effects—such as nausea, bloating, or cramps—can occur with butyrate supplementation, but serious toxicity is rare. Because butyric acid is metabolized rapidly by colonocytes and enters systemic circulation at relatively low levels, systemic toxicity is unlikely at intake levels generated physiologically. Still, individuals with inflammatory bowel disease may be more sensitive to doses in supplements, and gradual titration alongside professional guidance is recommended.

Butyric acid has not been widely studied for drug interactions in clinical pharmacology. Because it is rapidly metabolized in the gut and liver, significant interactions with systemic medications are not commonly reported. However, theoretical interactions may exist in contexts where butyrate influences inflammatory pathways or gut barrier function. For example, medications that alter gut microbiota—such as broad‑spectrum antibiotics—can reduce endogenous butyric acid production by depleting fermentative bacteria. Conversely, prebiotic and probiotic interventions designed to enhance SCFA production may interact with gut‑active medications. Patients taking drugs that affect gastrointestinal motility should consult clinicians when using butyrate supplements, as altered transit times could modify butyrate delivery and effects.

Common Forms: Sodium butyrate, Calcium butyrate, Encapsulated butyrate esters

Typical Doses: Several hundred mg to a few grams per day in clinical studies

When to Take: With meals or as advised by clinician

Best Form: Enteric‑coated butyrate preparations for colon delivery